Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

NCT00172055 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer Prostate

Interventions

DRUG: Zoledronic acid

Sponsor

Novartis Pharmaceuticals